InforMS: Winter 2020

Treating Multiple Sclerosis

Exploring the Changing Landscape of Disease Modifying Therapies in MS

Our understanding and ability to treat multiple sclerosis has evolved dramatically over the past 30 years. Prior to 1993, there were no approved therapies for MS. Fortunately, today, there are 23 approved disease modifying therapies (DMTs) to treat MS and the development of drugs is rapid and ongoing.

With so many DMTs now available, and several introduced just in the past year, it can be confusing to keep track and to understand the similarities and differences.

In this issue of InforMS, we provide an overview of the importance of DMTs, the current landscape of available treatment options, and potential future neuro-reparative and neuro-protective therapies.

The Importance of Early and Effective Treatment with DMTs

By Kerri Cechovic | The Rocky Mountain MS Center and our partners at the Rocky Mountain MS Center at University of Colorado advocate for a fundamental philosophy of maximizing lifelong brain health through early and effective treatment and adoption of a healthy lifestyle. This philosophy drives a core treatment model focused on early, highly effective treatment of the disease. The strategy starts with identifying MS as early as possible – in many cases, even before significant symptoms are apparent. Patients are treated with the latest and most effective MS drugs at the very earliest signs of MS, in an effort to slow or even stop the disease before it has the opportunity to do much lasting damage.

Read more